Current Atherosclerosis Reports

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	151
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	136
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	113
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	110
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	93
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	76
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	76
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	75
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease	69
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	66
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments	65
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	64
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	61
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart	57
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	53
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	50
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	49
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event	42
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis	41
Inflammation in the Peri-ACS Period: Ready for Prime Time?	40
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	40
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	38
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?	38
The Emerging Specialty of Cardio-Rheumatology	37
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	36

Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	35
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	33
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	33
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	31
Percutaneous Coronary Interventions in Women	31
Myeloid Cells in Abdominal Aortic Aneurysm	31
Lipoprotein(a): from Causality to Treatment	30
Low LDL-C: Is It all Good News?	29
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	29
The Role of Sleep in Cardiovascular Disease	29
Importance of Nutrition Security to CVD Prevention Efforts in the USA	29
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	28
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?	28
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	27
Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review	27
Transgender Cardiovascular Health: Practical Management for the Clinician	26
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	26
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	25
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	24
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	24
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	24
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	23
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference	23
Exploring the Role of SPARC in Atherosclerosis: Mechanisms and Potential Implications	23
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	22
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	22
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	22
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	22
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	21
Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges	21
Factors Affecting Circulating Phytosterol Levels: Toward an Integrated Understanding of Atherogenicity and Atheroprotection by Dietary and Circulating Phytosterols	21
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	20
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	20
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	20
Gene Regulatory Networks in Coronary Artery Disease	19
Cardiovascular Disease in the Middle East and North Africa, 1990–2021: Burden, Trends, and Risk Factors	19
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	19
HIV and Cardiovascular Disease Burden in Young Adults (18–25 years): A Review of Current Evidence	19
Clinical Management of Dyslipidemia in Infants and Toddlers	19
Cardiovascular Health and Disease in the Pakistani American Population	18
Expanding Clinical Indications for Cardiac CT: A Review of Its Current Utility in American and European Guidelines	18
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	17
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	17
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	17
What Causes Premature Coronary Artery Disease?	17
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	16
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review	16
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference	16
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults	16
Bempedoic Acid: for Whom and When	16

Natural Sirtuin1 Activators and Atherosclerosis: an Overview	16
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	16
Dietary Management of Atherogenic Dyslipidemia	15
Serial Coronary CTA for Monitoring Response to Lipid-Lowering Therapy: A Narrative Review	15
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	14
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	14
Fixed Combination for the Treatment of Dyslipidaemia	14
Utility of FFRCT in Patients with Chest Pain	14
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	14
Circular RNA role in Atherosclerosis Development and Progression	14
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?	14
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	14
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	14
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	13
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention	13
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	13
Apheresis: What Should a Clinician Know?	13
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	13
Cardiovascular Disease Burden among African Migrants	13
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	13
Correlation Between Oral Bacteria and Atherosclerotic Thrombotic Disease: Advances in Animal Model Studies	13
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges	12
Obicetrapib—the Rebirth of CETP Inhibitors?	12
Can Digital Health Solutions Fill in the Gap for Effective Guideline Implementation in Cardiovascular Disease Prevention: Hope or Hype?	12
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	12
Statins as Modulators of Epithelial to Mesenchymal Transition in Cardiovascular-Kidney-Metabolic Syndrome: a Comprehensive Review of Mechanisms and Therapeutic Implications	12
HDL as a Treatment Target: Should We Abandon This Idea?	12
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia	12
The TICE Pathway: Mechanisms and Potential Clinical Applications	12
Recent Advances in Coronary Computed Tomography Angiogram: The Ultimate Tool for Coronary Artery Disease	12
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation	12
S-Nitrosylation: Mechanistic Links between Nitric Oxide Signaling and Atherosclerosis	11
CETP Inhibitors: Should We Continue to Pursue This Pathway?	11
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy	11
How to Handle Elevated Triglycerides: Life after PROMINENT	11
The Atherosclerotic Plaque Microenvironment as a Therapeutic Target	11
Advances, Challenges, and Progress in Cardiac Rehabilitation in Chronic CVD Management	11
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?	11
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment	11
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?	11
Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan	11
Myocardial Bridge and Atherosclerosis, an Intimal Relationship	10
An Update on Nutrition Guidance for Cardiovascular Health	10
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?	10
Ancestral Variation in Lp(a): Epidemiology, Isoform Diversity, and Testing	10
Can We Mitigate Coronary Heart Disease Risk in Patients with Cancer?	10
Family Meals and Cardiometabolic Risk Factors in Young Children	10
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?	10
Gene Editing for the Treatment of Hypercholesterolemia	10
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?	10
Mechanisms Behind NAFLD: a System Genetics Perspective	10
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy	10
Unveiling the Sex-Based Divide: Exploring Sex Differences in Peripheral Artery Disease	10
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence	10
Artificial Intelligence-Enabled Point-of-Care Echocardiography: Bringing Precision Imaging to the Bedside	10
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes	10
Update on Sitosterolemia and Atherosclerosis	9
Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care	9
Biomarkers Differentiating Plaque Erosion from Stable Plaque	9
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes	9
Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?	9
Correction to: Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	9
Sport as Medicine for Dyslipidemia (and Other Risk Factors)	9
Correction to: Built Environment and Cardiovascular Diseases – Insights from a Global Review	9
JAM-A: Adhesion Receptor and Signaling Regulator in Atherosclerosis	9
Health Literacy is Essential to ASCVD Prevention in Youth	9
Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	9
Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence	9
The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations	8
Tackling the Cardio-Kidney-Metabolic Burden in Cancer	8
Mechanosensing and Mechanosignal Transduction in Atherosclerosis	8
ADAMTS7: a Novel Therapeutic Target in Atherosclerosis	8
Familial Combined Hyperlipidemia: Myth or Reality?	8
Updates in Small Interfering RNA for the Treatment of Dyslipidemias	8
Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries	8
Statin Intolerance: an Overview of US and International Guidance	8
Insight into the Mechanistic role of Colchicine in Atherosclerosis	8
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder	8
Inclisiran: How Widely and When Should We Use It?	8
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors	8

“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”	8
Impact of Sex Differences on Lipids and Statin Utilization	8
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes	8
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	8
Incidental Finding of Coronary and Non-Coronary Artery Calcium: What Do Clinicians Need To Know?	8
Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease	8
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus	7
Sex-based Differences in Complications Following Percutaneous Coronary Interventions	7
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia	7
Lp(a): A Rapidly Evolving Therapeutic Landscape	7
Built Environment and Cardiovascular Diseases – Insights from a Global Review	7
Novel Therapeutics for Familial Chylomicronemia Syndrome	7
Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?	7
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future	7
AI in Adipose Imaging: Revolutionizing Visceral Adipose Tissue, Ectopic Fat, and Cardiovascular Risk Assessment	7
Telomere Length: Implications for Atherogenesis	7